DANIELLE FOWLER: Open Payments
NPI 1053007831 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 28 payments from 9 companies in 2025. Trend: 2023 $60 · 2024 $776 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $288 |
| Novo Nordisk Inc | 5 | $135 |
| Amgen Inc. | 1 | $126 |
| Novartis Pharmaceuticals Corporation | 6 | $108 |
| E.R. Squibb & Sons, L.L.C. | 1 | $61 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 4 | $53 |
| ABIOMED | 2 | $37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Merck Sharp & Dohme LLC | 1 | $19 |
Products named: REPATHA, Wegovy, LEQVIO, FARXIGA, ELIQUIS, LifeVest, Ozempic, JARDIANCE.
Industry payments across ID — which companies pay providers there.
